Publications

2016

Andersson A, Bluwstein A, Kumar N, Teloni F, Traenkle J, Baudis M, Altmeyer M, Hottiger MO (2016). “PKCα and HMGB1 antagonistically control hydrogen peroxide-induced poly-ADP-ribose formation.” Nucleic Acids Res 44(16):7630-7645.

 

Antsiferova M, Piwko-Czuchra A, Cangkrama M, Wietecha M, Sahin D, Birkner K, Amann V, Levesque M, Hohl D, Dummer R, Werner S. Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. EMBO Molecular Medicine DOI 10.15252/emmm.201606493.

 

Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, and Boyman O. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Science Translational Medicine (2016) 8, 367ra166.

 

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 Nov 15;14(1):313.

 

Bartolomei, G., M. Leutert, M. Manzo, T. Baubec and M. O. Hottiger (2016). "Analysis of Chromatin ADP-Ribosylation at the Genome-wide Level and at Specific Loci by ADPr-ChAP." Mol Cell 61(3): 474-485.

 

Becker A, Zhang P, Allmann L, Meilinger D, Bertulat B, Eck D, Hofstaetter M, Bartolomei G, Hottiger MO, Schreiber V, Leonhardt H, Cardoso MC (2016). “Poly(ADP-ribosyl)ation of methyl CpG binding protein 2 regulates chromatin structure.” J Biol Chem 291(10):4873-4881

 

Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. Cell Rep. 2016 May 31;15(9):1884-92.

 

Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Sep 27.

 

Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, Goldinger S.M.. Noncutaneous Melanomas: A Single-Center Analysis. Dermatology 2016;232:22-29

 

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? J Immunother. 2016 Nov/Dec;39(9):379-382.

 

Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-Séguin N, Del Marmol V, Dummer R, Jemec GB, Malvehy J, Peris K, Puig S, Stratigos AJ, Zalaudek I, Pellacani G. Real-world approach to actinic keratosis management: Practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2016 Oct 31:1-50.

 

Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Apr 7. pii: S0190-9622(16)01491-2.

 

Eggermont A, Suciu S, Rutkowski P, Kruit W, Punt C, Dummer R, Salès F, Keiholz U, de Schaetzen G, Testori A, for the EORTC Melanoma Group. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIBeIII cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. EJC 55 (2016) 111-121.

 

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016 Oct 7.

 

Fan Y, Lee S, Wu G, Easton J, Yergeau D, Dummer R, Vogel P, Kirkwood JM, Barnhill RL, Pappo A, Bahrami A. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol. 2015 Sep 24.

 

Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget. 2016 Nov 18.

 

Furrer A, Hottiger MO, Valaperti A (2016). “Absent in Melanoma 2 (AIM2) limits pro-inflammatory cytokine transcription in cardiomyocytes by inhibiting STAT1 phosphorylation.” Mol Immunol 74:47-58.

 

Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016 Mar 8 clincanres.2872.2015.

 

Hasan Ali O, Diem S, Markert F, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.
Oncoimmunology, 5:e1231292, 2016.

 

Henning B, Stieger P, Kamarachev J, Dummer R, Goldinger SM. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Res. 2016 Jun;26(3):304-7.

 

Hofer A, Marques E, Kieliger N, Gatter SK, Jordi S, Ferrari E, Hofmann M, Fitzpatrick TB, Hottiger MO, Jessen HJ (2016). “Chemoselective Dimerization of Phosphates.” Org Lett 18(13):3222-3225.

 

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:190-209.

 

Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque M, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C , Nonomura Y , Kabashima K, Dummer R, French L. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages, Scientific Reports, Nature 2016.

 

Imhof L, Dummer R, Dreier J, Kolm I, Barysch M. A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines. Dermatol Surg. 2016;42:853-857.

 

Jenni D, Karpova MB, Mühleisen B, Mangana J, Dreier J, Hafner J, Dummer R. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open Cancer Horizons 2016;1:e000003 DOI:10.1136/esmoopen-2015-000003.

 

Kulig P, Burkhard S, Mikita-Geoffroy J, Croxford AL, Hovelmeyer N, Gyulveszi G, Gorzelanny C, Waisman A, Borsig L and Becher B. IL17A-Mediated Endothelial Breach Promotes Metastasis Formation. Cancer Immunology Research. 2016;4(1):26-32.

 

Léger K, Hopp AK, Fey M, Hottiger MO (2016). “ARTD1 regulates cyclin E expression and consequently cell-cycle re-entry and G1/S progression in T24 bladder carcinoma cells.” Cell Cycle 15(15):2042-2052.

 

Leinweber N, Dziunycz PJ, French LE, Wüthrich R, Serra AL, Hofbauer GF. Considerable loss of information on skin cancer occurrence and non-adherence to clinical practice guideline in renal transplant recipients.
J Eur Acad Dermatol Venereol, 30:1399-401, 2016.

 

Ma B, Hottiger MO (2016). “Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation.” Front Immunol 7:378.

 

Martello R, Leutert M, Jungmichel S, Bilan V, Larsen SC, Young C, Hottiger MO, Nielsen ML: Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. Nat. Commun.  7:12917, 2016.

 

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology 2015;173:1462-1470

 

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16.

 

Niessner H, Schmitz J, Tabatabai G, Schmid A, Calaminus C, Sinnberg T, Weide B, Eigentler T, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders M, Meinhardt M, Baretton G, Dummer R, Flaherty K, Pichler B, Kulms D, Westphal D, Meier F.  PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.

 

Ohs I, van den Broek M, Nussbaum K, Munz C, Arnold SJ, Quezada SA, Tugues S and Becher B. Interleukin-12 bypasses common gamma-chain signalling in emergency natural killer cell lymphopoiesis. Nat Commun. 2016;7(13708.

 

Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. 2016 Oct 24.

 

Rehefeldt-Erne S, Nägeli MC, Winterton N, Felderer L, Weibel L, Hafner J, Dummer R. Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. Dermatology 2016

 

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clin Cancer Res. 2016 22(8) April 15,2016.

 

Rozati S, Kempf W, Ostheeren-Michaelis S, Bode-Lesniewska B, Zimmermann DR, Dummer R, Cozzio A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J Clin Oncol 2016 April 10;34(11):e93-6.

 

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O’Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert J, Hille D, Ebbinghaus S, Peter Kang S, Zhou W, Ribas A. Health-related quality of life in the randomized KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer 67 (2016) 46-54.

 

Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016 Mar 14;29(3):270-84.

 

Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, Raselli T, Frey-Wagner I, Gutte PM, Grutter MG, Beer HD, Contassot E, Chan AC, Dai X, Rawlings DJ, Mair F, Becher B, Falk W, Fried M, Rogler G and Scharl M. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest. 2016;126(11):4388

 

Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R. An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. Br J Dermatol. 2016 Nov;175(5):966-978. doi: 10.1111/bjd.14727. Epub 2016 Sep 19

 

Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. Eur J Cancer 2016 Jun:65:130-138.

 

Valenta T, Degirmenci B, Moor AE, Herr P, Zimmerli D, Moor MB, Hausmann G, Cantu C, Aguet M, Basler K. 2016. Wnt ligands secreted by sub-epithelial mesenchymal cells are essential for the survival of intestinal stem cells and gut homeostasis. Cell Reports 15:911-918.

 

Wang C, Qu C, Alippe Y, Bonar SL, Civitelli R, Abu-Amer Y, Hottiger MO, Mbalaviele G (2016). “Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast maturation.” Cell Death Dis 7:e2153

 

Weide B, Martens A, Hassel JC, Berking C, Postow MA,  Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016 May 16. pii: clincanres.0127.2016.

 

Woytschak J, Keller N, Krieg C, Impellizzieri D, Thompson RW, Wynn TA, Zinkernagel AS, and Boyman O. Type 2 interleukin-4 receptor signaling in neutrophils antagonizes their expansion and migration during infection and inflammation.
Immunity (2016) 45:172-84.

 

Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:210-25.

2015

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO. European Evidence-based Consensus:Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2015, 945–965 

 

Arenas-Ramirez N, Woytschak J, and Boyman O. Interleukin-2: biology, design and application.
Trends in Immunology (2015) 36:763-77.

 

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014: J Transl Med. 2015 Nov 30;13(1):374.

 

Baggiolini A, Varum, S, Mateos JM, Bettosini D, John N, Bonalli M, Ziegler U, Dimou L, Clevers H, Furrer R, and Sommer L (2015). Premigratory and migratory neural crest cells are multipotent in vivo. Cell Stem Cell, 16(3):314-322.

 

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst D, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015 May 14.

 

Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A, Eiwegger T, Firinu D, Harr T, Knol E, Matucci A, Palomares O, Schmidt-Weber C, Simon HU, Steiner U, Vultaggio A, Akdis CA, and Spertini F. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.
Allergy (2015), 70:727-54.

 

Boyman O, Kolios AG, and Raeber ME. Modulation of T cell responses by IL-2 and IL-2 complexes.
Clinical and Experimental Rheumatology (2015) 33(4 Suppl 92):54-7.

 

Bransi A, Salgado O, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, van den Broek M. 2015. Rational combination of immunotherapy with clinical efficacy in mice with advanced cancer. Cancer Immunology Res. 3:1279-1288.

 

Brüggen MC, Petzelbauer P, Greinix H, Contassot E, Jankovic D, French LE, Socié G, Rabitsch W, Kuzmina Z, Kahls P, Knobler R, Stingl G, Stary G. Epidermal Elafin Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. J Invest Dermatol, 135:999-1006, 2015

 

Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raijmakers M, Goldinger S, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology 2015;16:42,

 

Curioni-Fontecedro A, Pitocco R, Schoenewolf NL, Holzmann D, Soldini D, Dummer R, Calvieri S, Moch H, Mihic-Probst D, Fitsche A. Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. BioMed Research International 2015;5:

 

Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, Goldinger S. Noncutaneous Melanomas: A Single-Center Analysis: Dermatology 2015.

 

Deml KF, Schildhaus HU, Comperat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, Gabler N, Grobholz R, Hailemariam S, Hinze R, Knuchel R, Lhermitte B, Nesi G, Rudiger T, Sauter G, Moch H. (2015). Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Path. 39:889-901

 

Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, on behalf of the ESMO Guidelines Committee, Cutaneous melanoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:126-132

 

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, De Pril Veerle, Gurunath RK, De Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology 2015;March 31 S1470-2045(15)70122-1.

 

Eppler E, Janas E, Link K, Weidmann L, Bischofberger H, Wenger M, Tinguely M, Schraml P, Moch H, Fellbaum C. (2015). Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells. Cell Tissue Res. 359:841-51.

 

Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun R, Dummer R, Goldinger SM. Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status. Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347 (Impact Factor 4.275)Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger S. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol 2015;25(2):177-80

 

Freiberger, SN, Cheng, PF, Iotzova-Weiss, G, Neu, J, Liu, Q, Dziunzcz, PJ, Zibert, JR, Dummer, R, Skak, K, Levesque, MP, Hofbauer, GF. (2015). Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics 14: (9) 2132—2142.

 

Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SPG, Grippo JF. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharma Res Per 2015;3:e00113

 

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label,randomised trial: Lancet Oncol 2015; 16: 1389–98

 

Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini AA, Mitev V, Dummer R, Kazakov DV, French LE, Hoetzenecker W, Cozzio A. Expression of CD164 on Malignant T Cells in Sézary Syndrome: Acta Derm Venereol. 2015 Nov 2.

 

Guenova, E, Skabytska, Y, Hoetzenecker, W, Weindl, G, Sauer, K, Tham, M, Kim, KW, Park, JH, Seo, JH, Ignatova, D, Cozzio, A, Levesque, MP, Volz, T, Köberle, M, Kaesler, S, Thomas, P, Mailhammer, R, Ghoreschi, K, Schäkel, K, Amarov, B, Eichner, M, Schaller, M, Clark, RA, Röcken, M, Bidermann, T. (2015). IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proceedings of the National Academy of Sciences 112:7 2163—2168.

 

Heppt MV, Reinholz M, Tietze JK, Kerl K, French LE, Berking C, Kamarashev J. Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population.
Eur J Dermatol, 25:127-32, 2015.

 

Hottiger, M. O. (2015). "Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?" Expert Opin Ther Targets 19(9): 1149-1152.

 

Hottiger, M. O. (2015). "Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics." Annu Rev Biochem 84: 227-263.

 

Hottiger, MO. (2015). "Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?" Expert Opin Ther Targets 19(9): 1149-1152.

 

Iotzova-Weiss G, Dziunycz PJ, Freiberger SN, Läuchli S, Hafner J, Vogl T. French LE, Hofbauer GF. S100A8/A9 Stimulates Keratinocyte Proliferation in the Development of Squamous Cell Carcinoma of the Skin via the Receptor for Advanced Glycation-End Products. PloS One, 10:e0120971, 2015.

 

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward N, Perlina A, Piris A, Zhang T, Halaban R, Herlyn M, Brown K, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Downregulation of the ubiquitin ligase RNF125 underlies restistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Reports 9 June 2015, 1458-1473.

 

Kleffel S, Posch C, Barthel SR, Müller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Instrinsic PD-1 Receptor Functions Promote Tumor Growth. CellPress  2015;162:1242-1256.

 

Kunz M, Urosevic-Maiwald M, Goldinger SM, Frauchiger AL, Dreier J, Belloni B, Mangana J, Jenni D, Dippel M, Cozzio A, Guenova E, Kamarachev J, French LE, Dummer R. Efficacy and safety or oral alitretinoin in severe oral lichen planus – results of a prospective pilot study: JEADV 2015.

 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey C.L, Lao C.D, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferruci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postwo MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine 2015 May 31.

 

Lau E, Sedy J, Sander C, Shaw MA, Feng Y, Scortegagna M, Claps G, Robinson S, Cheng P, Srivas R, Soonthornvacharin S, Ideker T, Bosenberg M, Gonzalez R, Robinson W, Chanda SK, Ware C, Dummer R, Hoon D, Kirkwood JM, Ronai ZA. Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene 2015 Nov 12;34(46):5739-48.

 

Lee S, Barnhill R, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT Promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Nature Scientificreports 10 June 2015.

 

Lehmann, M., E. Pirinen, A. Mirsaidi, F. A. Kunze, P. J. Richards, J. Auwerx and M. O. Hottiger (2015). "ARTD1-induced poly-ADP-ribose formation enhances PPARgamma ligand binding and co-factor exchange." Nucleic Acids Res 43(1): 129-142. 

 

Levesque MP, Dummer R, Beerenwinkel N. 2015. Perturbing resistance: a network perspective. Pigment Cell Melanoma Res. DOI: 10.1111/pcmr.12431

 

Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity: Lancet Oncol. 2015 Jan;16(1):15-7.

 

Ma, B., M. Fey and M. O. Hottiger (2015). "WNT/beta-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-kappaB target genes." J Cell Sci 128(14): 2430-2436.

 

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?: PLoS One. 2015 Oct 1;10(10):e0139438.

 

Mangana J, Felderer L, Cheng P, French L, Dummner R, Schad K. Diffuse cutaneous melanosis associated with malignant melanoma. Ann Dermatol 2015 Dec;27(6):780-1.

 

Marroquin Belaunzaran O, Kleber S, Schauer S, Hausmann M, Nicholls F, van den Broek M, Payeli S, Ciurea a, Milling S, Stenner F, Shaw J, Kollnberger S, Bowness P, Petrausch U, Renner C. 2015. HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. PLOS ONE DOI:10.1371/journal.pone.0130811.

 

Marschall K, Hoernes M, Bitzenhofer-Gruber M, Jandus P, Duppenthaler A, Wuillemin WA, Rischewski J, Boyman O, Heininger U, Hauser T, Steiner U, Posfay-Barbe K, Seebach J, Recher M, Hess C, Helbling A, and Reichenbach J; Swiss PID Registry Working Group.
Clinical and Experimental Immunology (2015) 182:45-50.

 

Matsushita S, Krähenbühl L, Otsuka A, Mihic-Probst D, Cheng P, Dummer R, Goldinger S. Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma. The Journal of Dermatology 2015;42:1-2.

 

Mehra T, Ikenberg K, Moos RM, Benz R, Nair G, Schanz U, Haralambieva E, Hoetzenecker W, Dummer R, French LE, Guenova E, Cozzio A. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome: JAMA Dermatol. 2015 Jan;151(1):73-7.

 

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis K, Combermale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomized, double-blind phase 2 trial. Lancet Oncology 2015 May 14.

 

Minotti, R., A. Andersson and M. O. Hottiger (2015). "ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation." Mol Cell Biol 35(18): 3189-3199.

 

Mohr Peter, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatments of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologie Cooperative Oncology Group Trial. Journal of Clinical Oncology 2015;33:4077-4084.

 

Muller-Edenborn, K., K. Leger, J. F. Glaus Garzon, C. Oertli, A. Mirsaidi, P. J. Richards, H. Rehrauer, P. Spielmann, D. Hoogewijs, L. Borsig, M. O. Hottiger and R. H. Wenger (2015). "Hypoxia attenuates the proinflammatory response in colon cancer cells by regulating IkappaB." Oncotarget 6(24): 20288-20301.

 

Nowicka AM, Hauselmann I, Borsig L, Bolduan S, Schindler M, Schraml P, Heikenwalder M, Moch H. (2015). A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene. doi: 10.1038/onc.2015.400.

 

Otsuka A, Levesque MP, Dummer R, Kabashima K. 2015. Hedgehog signaling in basal cell carcinoma. J. Dermatol Sci 78:95-100.

 

Otsuka A, Dreier J, Cheng PF, Nageli M, Lehmann H, Felderer L, Frew IJ, Matsushita S, Levesque MP, Dummer R. Hedgehog pathway inhibitors promote adaptive immune responses in Basal Cell Carcinoma. Clin Cancer Res. 2015;21:1289-97

 

Pflueger D, Mittmann C, Dehler S, Rubin MA, Moch H, Schraml P. (2015). Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. BMC Genomics. 16:247.

 

Raaijmakers, MIG, Widmer, DS, Maudrich, M, Koch, T, Langer, A, Flace, A, Schnyder, C, Dummer, R, Levesque, MP. (2015). A new live cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology 24: (5) 377—380.

 

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SK, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Sosman JA, Goldiner SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li YN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18.

 

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30-9.

 

Rosenthal, F., P. Nanni, S. Barkow-Oesterreicher and M. O. Hottiger (2015). "Optimization of LTQ-Orbitrap Mass Spectrometer Parameters for the Identification of ADP-Ribosylation Sites." J Proteome Res 14(9): 4072-4079.

 

Ruf M, Mittmann C, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. 2015. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clin. Cancer Res. 21:890-898.

 

Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells. Exp Dermatol. 2015 Jan;24(1):22-8.

 

Schreiner B, Ingold-Heppner B, Pehl D, Locatelli G, Berrit-Schonthaler H and Becher B. Deletion of jun proteins in adult oligodendrocytes does not perturb cell survival, or myelin maintenance in vivo. PLoS ONE. 2015;10(3):e0120454.

 

Schreiner B, Romanelli E, Liberski P, Ingold-Heppner B, Sobottka-Brillout B, Hartwig T, Chandrasekar V, Johannssen H, Zeilhofer HU, Aguzzi A, Heppner F, Kerschensteiner M and Becher B. Astrocyte Depletion Impairs Redox Homeostasis and Triggers Neuronal Loss in the Adult CNS. Cell Rep. 2015;12(9):1377-84.

 

Shain Hunter A, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D’Arrigo C, Robson A, Path FRC, Bastian BC. The Genetic Evolution of Melanoma from Precursor Lesions: N Engl J Med 2015;373:1926-36.

 

Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, Dummer R, Santoro R, Cinelli P, Sommer L. Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. PLoS Genet 2015;11:e1004877.

 

Sollberger G, Strittmatter GE, Grossi S, Garstkiewicz M, dem Keller UA, French LE, Beer HD. Caspase-1 Activity is required for UVB-Induced Apoptosis of Human Keratinocytes. J Invest Dermatol, 135:1395-404, 2015.

 

Sullivan R, LoRusso P, Boerner S, Dummer R. Achievements and challenges of molecular targeted therapy in melanoma: See comment in PubMed Commons belowAm Soc Clin Oncol Educ Book. 2015:177-86.

 

Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, van den Broek M. Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. Immunity 2015;42:1-11.

 

Surace L, Scheifinger N, Gupta A, van den Broek M. 2015. Radiotherapy supports tumor-specific immunity by acute inflammation. Oncoimmunology, DOI: 10.1080/2162402X.2015.1060391.

 

Surace L, Guckenberger M, van den Broek M. 2015. Radiation holidays stimulate tumor immunity. Oncotarget 6:15716-15717.

 

Tackenberg S, Gehrig A., Dummer R, Navarini AA. External Beam Radiotherapy of Extramammary Paget Disease. Cutis 2015;95:109-112.

 

Tugues S, Burkhard SH, Ohs I, Vhrolings M, Nussbaum K, vom Berg J, Kulig P and Becher B. New insights into IL-12 mediated tumor suppression. Cell Death Differ. 2015;22(2):237-46.

 

Urosevic-Maiwald M, Barysch MJ, Cheng PF, Karpova MB, Steinert H, Okoniewski MJ, Dummer R. In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. Oncolmmunology 2015;4:2, e988458.

 

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide Benjamin, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA4 blockade in metastatic melanoma: Sciencexpress 2015;1:10.1126.

 

Zingg D, Schaefer SM, Debbache J, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, and Sommer L. The epigenetic modifier EZH2 drives metastatic melanoma through a repression of a bifunctional tumour suppressor gene set.
Nature Communications (2015), 6:6051.

2014

Amin MB, Smith SC, Agaimy A, Argani P, Comperat EM, Delahunt B, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. The American journal of surgical pathology. 2014;38:871-4.

 

Baggiolini, A., Varum, S., Mateos, J., Bettosini, D., John, N., Bonalli, M., Ziegler, U., Dimou, L., Clevers, H., Furrer, R., Sommer, L. (2015). Premigratory and Migratory Neural Crest Cells Are Multipotent In Vivo. Cell Stem Cell 16(3) 314-322.

 

Barysch MJ, Levesque MP, Cheng P, Karpova MB, Mihic-Probst D, Civenni G, Shakova O, Sommer L, Biedermann T, Scheistl C, Dummer R. Coexpression of SOX10/CD271 (p75NTR) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. Dermatopathology 2014;1:35-46

 

Becher B, Schlitzer A, Chen J, Mair F, Sumatoh HR, Teng KW, Low D, Ruedl C, Riccardi-Castagnoli P, Poidinger M, Greter M, Ginhoux F, Newell EW. High-dimensional analysis of the murine myeloid cell system. Nat Immunol. 15:1181-1189, 2014

 

Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9:239-47.

 

Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia. 2014;16:14-20.

 

Bode PK, Thielken A, Brandt S, Barghorn A, Lohe B, Knuth A, et al. Cancer testis antigen expression in testicular germ cell tumorigenesis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27:899-905.

 

Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumaol 10:612-627, 2014.

 

Burkhard SH, Mair F, Nussbaum K, Hasler S, Becher B. T cell contamination in flow cytometry gating approaches for analysis of innate lymphoid cells. PLoS One, 9(4):e94196, 2014.

 

Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 4:415-421, 2014.

 

Curioni-Fontecedro A, Martin V, Vogetseder A, Knuth A, Moch H, Soldini D, et al. Chromosomal aberrations of cancer-testis antigens in myeloma patients. Hematological oncology. 2014.

 

Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. Journal of molecular endocrinology. 2014;52:181-9.

 

Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Basal cell carcinomas in a tertiary referral centre- a systematic analysis. Br J Dermatol 2014 [Epub ahead of print]

 

Dreier J, Dummer R, Felderer L, Nägeli M, Gobbi S, Kunstfeld R. Emerging drugs and conbination strategies for basal cell carcinoma. Expert Opin Emerg Drugs 19:353-365, 2014.

 

Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon-γ) in Primary Cutaneous B-cell Lymphomas: A Phase II Clinical Trial. PLoS One 2014;9:e83670

 

Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary Syndrome). Ann Oncol 2014 [Epub ahead of print]

 

Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD. Vemurafenib in patients with BRAFV600 mutationpositive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer 2014;50:611-21

 

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. To B-(RAF) or Not to Be. J Invest Dermatol 2014;134:1200-1

 

Dummer R. Precision medicine and skin cancer therapy: dealing with a moving target. Editorial. Curr Opin Oncol 2014;26:182-183

 

Engeli L, Moergeli H, Binder M, Drabe N, Meier C, Buechi S, Dummer R, Jenewein J. Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. Eur J Cancer Care (Engl) 2014 [Epub ahead of print]

 

Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D. Treatment Algorithms in Stage IV Melanoma. Am J Ther. 2014 Jan 9. [Epub ahead of print]

 

Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014 Jan 30. pii: S1470-2045(14)70007-5 [Epub ahead of print]

 

Friemel J, Rechsteiner MP, Frick L, Boehm F, Struckmann K, Sigg M, et al. Intratumor heterogeneity in hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014.

 

Gehrke S, Otsuka A, Huber R, Meier B, Kistowska M, Fenini G, Cheng P, Dummer R, Kerl K, Contassot E, French LE. Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages. J Dermatol Sci 2014;74:167-9

 

Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs. 2014 Jan 8. [Epub ahead of print]

 

Guenova E, Schanz S, Hoetzenecker W, Desimone JA, Mehra T, Voykov B, Urosevic- Maiwald M, Berneburg M, Dummer R, French LE, Kerl K, Kamarachev J, Fierlbeck G, Cozzio A. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol. 2014 [Epub ahead of print]

 

 

Hartmann FJ, Khademi M, Aram J, Ammann S, Kockum I, Constantinescu C, Gran B,  Piehl F, Olsson T, Codarri L, Becher B. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat Commun. 3;5:5056, 2014.

 

Hell MP, Duda M, Weber TC, Moch H, Krek W. Tumor suppressor VHL functions in the control of mitotic fidelity. Cancer research. 2014;74:2422-31.

 

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, et al. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. The Journal of pathology. 2014;234:239-52.

 

Kempf W, Kazakov DV, Rütten A, Rupec RA, Talarcik P, Ballová V, Kerl K, Dummer R, Lautenschlager S, Zimmermann DR, Tinguely M. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: A report of 4 cases of a rare variant. J Am Acad Dermatol 2014 [Epub ahead of print]

 

Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PloS one. 2014;9:e100041.

 

Léger K, Bär D, Savić N, Santoro R, Hottiger MO. ARTD2 activity is stimulated by RNA. Nucleic Acids Res. 2014 Apr;42(8):5072-82.

 

Lenggenhager D, Curioni-Fontecedro A, Storz M, Shakhova O, Sommer L, Widmer DS, Seifert B, Moch H, Dummer R, Mihic-Probst D. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. Transl Oncol. 2014 [Epub ahead of print]

 

Lenggenhager D, Curioni-Fontecedro A, Storz M, Shakhova O, Sommer L, Widmer DS, et al. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. Translational oncology. 2014;7:206-12.

 

Lenggenhager D., Curioni-Fontecedro A., Storz M., Shakhova O., Sommer L., Seifert B., Moch H., Dummer R., Mihic-Probst D. (2014). An aggressive hypoxia related subpopulation of melanoma cells is TRP-2 negative. Translational Oncology, 7(2):206-12.

 

Lohri C, Hutzli Schaltegger C, van den Broek M, Wenger R, Ruegg C, Fink D, Fehr M, Knuth A, Zweifel M. 2014. Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer Res. 34:4693-4700.

 

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 [Epub ahead of print]

 

McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A. Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50:774-783

 

Mehra T, Ikenberg K, Moos RM, Benz R, Nair G, Schanz U, Haralambieva E, Hoetzenecker W, Dummer R, French LE, Guenova E, Cozzio A. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome. JAMA Dermatol. 2014 Oct 8

 

Meller S, Bicker A, Montani M, Ikenberg K, Rostamzadeh B, Sailer V, et al. Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. Virchows Archiv : an international journal of pathology. 2014;465:419-27.

 

Moch H, Lukamowicz-Rajska M. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2alpha regulation. Cancer discovery. 2014;4:22-4.

 

Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Biomarkers in renal cancer. Virchows Archiv : an international journal of pathology. 2014;464:359-65.

 

Montavon G, Jauquier N, Coulon A, Peuchmaur M, Flahaut M, Bourloud KB, Yan P, Delattre O, Sommer L, Joseph JM, Janoueix-Lerosey I, Gross N, Mühlethaler-Mottet A. (2014). Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget. 5(12):4452-66.

 

Nägeli MC, Dummer R. Vismodegib (Erivedge®). Schweiz Med Forum 2014;14:284-286

 

Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC clinical pathology. 2014;14:10.

 

Rechsteiner M, Muller R, Reineke T, Goede J, Bohnert A, Zhong Q, et al. Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Experimental hematology & oncology. 2014;3:18.

 

Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, et al. A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014.

 

Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Hedgehog Inhibitor Sonidegib (LDE225) in Patients With Advanced Solid Tumors. Clin Cancer Res 2014;20:1900-1909

 

Rosenthal F, Hottiger MO. Identification of ADP-ribosylated peptides and ADP-ribose acceptor sites. Front Biosci (Landmark Ed). 2014 Jun 1;19:1041-56.

 

Rosalia RA, Arenas-Ramirez N, Bouchaud G, Raeber ME, Boyman O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr Opin Chem Biol. Dec 23:39-46, 2014.

 

Rozati S, Kempf W, Ostheeren-Michaelis S, Bode-Lesniewska B, Zimmermann DR,Dummer R, Cozzio A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J Clin Oncol 2014 Sep 29. [Epub ahead of print]

 

Ruf M, Mittmann C, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. 2015. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clin. Cancer Res. 21:890-898.

 

Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol 2014;25:700-6

 

Schoenewolf NL, Belloni B, Simcock M, Tonolla S, Vogt P, Scherrer E, Holzmann D, Dummer R. Clinical implications of distinct metastasizing preferences of different melanoma subtypes. Eur J Dermatol 2014;24:236-41

 

Schwarz, D., Varum, S., Zemke, M., Scholer, A., Baggiolini, A., Draganova, K., Koseki, H., Schubeler, D., and Sommer, L. (2014). Ezh2 is required for neural crest-derived cartilage and bone formation. Development 141, 867-877.

 

Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, Dummer R, Santoro R, Cinelli P, Sommer L. (2015). Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. PLoS Genetics. 28;11(1)

 

Sommer L. (2014). Open questions: development of tumor cell heterogeneity and its implications for cancer treatment. BMC Biol, 5;12:15. doi: 10.1186/1741-7007-12-15..

 

Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85-9.

 

Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. 2014. Cell Death Differ. In press.

 

Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014;25:1437-41

 

Varga Z, Tubbs RR, Moch H. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PloS one. 2014;9:e105961.

 

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C. Fr in Onc 2014:4;227.

 

Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1. Nature cell biology. 2014.

 

Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, et al. Metabolic Activation of Intrahepatic CD8(+) T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. Cancer Cell. 2014;26:549-64.

 

Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwalder M, Schraml P, et al. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. British journal of cancer. 2014;110:686-94.

 

Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, Sommer L. (2015) The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 22; 6:6051

2013

Iolyeva M, Aebischer D, Proulx ST, Willrodt AH, Ecoiffier T, Häner S, Bouchaud G, Krieg C, Onder L, Ludewig B, Santambrogio L, Boyman O, Chen L, Finke D, Halin C. 2013. Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage. Blood 122:2271-81.

 

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, Hemmi S, Dummer R, Levesque MP. 2013. Hypoxia contributes to melanoma heterogeneity by triggering HIF1a-dependent phenotype switching. J Invest. Dermatol. 133:2436-2443.

 

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. 2013. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 5:169-182.

 

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. 2013. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494:251-254.

 

Rozati S, Naef L, Levesque MP, French LE, Dummer R. 2013. Real-life Experience With Pegylatet Interferon and Conventional Interferon in Adjuvant Melanoma Therapy. J Immunother. 36:52-56.

 

Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, Dummer R, Belloni B. 2013. RASopathic Skin Eruptions during Vemurafenib Therapy. PLoS One. 8:e58721.

 

Muehleisen B, Pazhenkottil A, French LE, Hofbauer GF. 2013. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration. JAMA Dermatol. 149:618-20.

 

Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber F, Guarda G, Follo M, Pfeifer D, Tardivel A, Ludigs K, Bouazzaoui A, Kerl K, Fischer J, Haas T, Schmitt-Gräff A, Manoharan A, Müller L, Finke J, Martin S, Gorka O, Peschel C, Ruland J, Idzko M, Duyster J, Holler E, French LE, Poeck H, Contassot E, Zeiser R. 2013. The Nlrp3-inflammasome regulates acute graft-versus-host disease.
J Exp Med. 210:1899-1910.

 

Gupta A, Nuber N, Esslinger E, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, van den Broek M. 2013. A novel human-derived monoclonal  antibody  against  NY-ESO-1  improves  the  efficacy  of  chemotherapy.  Cancer Immunity, 13:3-11.

 

Walter A,  Schäfer  M,  Matter  C,  Urosevic-Maiwald  M, Belloni  B,  Schönewolf  N,  Cecconi  V,  Kulig  P, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, van den Broek M. 2013. Aldara activates two independent immune defense pathways. Nat. Commun. 4:1560 doi: 10.1038/ncomms2566.

 

Braumüller H, Wieder T, Fischer S, Brenner E, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez  L, Fend F, Schaller M, Schulze-Osthoff  K, Röcken M. 2013. Th1 cell cytokines drive cancer into senescence. Nature, 494:361-365.

 

Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanackovic D, Knuth A and van den Broek M. 2013. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients. Leukemia, 27:1767-1769.

 

Dannenmann S, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. 2013. Myeloid cells promote progression of clear cell renal cell carcinoma. OncoImmunology, 2: eLocation ID: e23429.

 

von Boehmer L, Landshammer A, Bode P, Nuber N, Ritter G, Old L, Moch H, Jäger E, Knuth A, van den Broek M. 2013. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immunity 13:12-18.

 

Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, van den Broek M. 2013. Radiotherapy of human  sarcoma  promotes  an  intratumoral  immune  effector  signature.  Clin.  Cancer  Res. 19:4843-4853.

 

Schuberth P, Hagedorn  C, Jensen  S, Gulati  P, van  den  Broek  M, Mischo  A, Soltermann  A, Jüngel  A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U. 2013. Treatment of malignant pleural mesothelioma by fibrobast activation protein-specific re-directed T cells. J. Transl. Med. 11:187-197.

 

Dannenmann S, Hermanns  T, Bransi A, von Boehmer  L, Matter C, Stevanovic  S, Schraml  P, Moch H, Knuth A, van den Broek M. 2013. Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunology Res. OnlineFirst September 25, 2013; doi:10.1158/2326-6066.CIR-13-0113.

 

Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, van den Broek M, Renner C, Mischo A, Petrausch U. 2013. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T cells in a cell-free system.  Anticancer Res. 33:4189-4201.

 

Harris ML, Buac K, Shakhova O, Hakami RM, Wegner M, Sommer L, Pavan WJ. 2013. A dual role for Sox10 in the maintenance of the postnatal melanocyte lineage and the differentiation of melanocyte stem cell progenitors. PLoS Genet. e1003644.

 

Shakhova O, Sommer L. 2013. Testing the cancer stem cell hypothesis in melanoma: The clnics will tell. Cancer Lett. 338:74-81.

 

Morf MK, Rimann I, Alexander M, Roy P, Hajnal A. 2013. The Caenorhabditis elegans homolog of the Opitz syndrome gene, madd-2/Mid1, regulates anchor cell invasion during vulval development. Dev Biol. 374:108-114.

 

Robert C, Dummer C, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer St, Middleton MR. 2013. Lancet Oncol.14:733-740.

 

Dummer R. 2013. Treating basal-cell carcinoma in a real life setting. Lancet Oncol. 14:572-573.

 

Dummer R, Rozati S, Guenova E, Cozzio A. 2013. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphoma. Future Oncol. 9:1061-1064.

 

Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. 2013. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin. Pharmacother. 14:1307-1318.

 

Rolfs F, Hiber M, Gruber F, Bohm F, Pfister HJ, Bochkov VN, Tschachler E, Dummer R, Hohl D, Schafer M, Werner S. 2013. Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Res. 73:3460-3469.